JUDITH ANNE SHIZURU

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint The biology of allogeneic hematopoietic cell resistance
    Judith A Shizuru
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:S2-7. 2010
  2. ncbi request reprint Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system
    Judith A Shizuru
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, California 94305, USA
    Annu Rev Med 56:509-38. 2005
  3. ncbi request reprint Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Schol of Medicine, 300 Pasteur Dr, H3249, MC 5623, Stanford, CA 94305 5623, USA
    Blood 105:2300-6. 2005
  4. doi request reprint Tolerance and chimerism after renal and hematopoietic-cell transplantation
    John D Scandling
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    N Engl J Med 358:362-8. 2008
  5. ncbi request reprint Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
    Laura J Johnston
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 11:47-55. 2005
  6. pmc Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation
    Antonia M S Müller
    Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 107:14721-6. 2010
  7. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
  8. pmc The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
    Irving L Weissman
    Stanford Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA 94304 1334, USA
    Blood 112:3543-53. 2008
  9. pmc Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma
    Sally Arai
    Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:1145-54. 2010
  10. ncbi request reprint Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
    Susanne Auffermann-Gretzinger
    Division of Oncology and Bone Marrow Transplantation, Department of Medicine, The Blood Center, Stanford University Medical Center, CA 94305, USA
    Blood 99:1442-8. 2002

Collaborators

Detail Information

Publications33

  1. doi request reprint The biology of allogeneic hematopoietic cell resistance
    Judith A Shizuru
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:S2-7. 2010
    ....
  2. ncbi request reprint Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system
    Judith A Shizuru
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, California 94305, USA
    Annu Rev Med 56:509-38. 2005
    ....
  3. ncbi request reprint Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Schol of Medicine, 300 Pasteur Dr, H3249, MC 5623, Stanford, CA 94305 5623, USA
    Blood 105:2300-6. 2005
    ..003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for reduced-intensity allografting may adversely affect T-cell engraftment and survival outcome...
  4. doi request reprint Tolerance and chimerism after renal and hematopoietic-cell transplantation
    John D Scandling
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    N Engl J Med 358:362-8. 2008
    ..Adverse events requiring hospitalization were limited to a 2-day episode of fever with neutropenia. The patient has had neither rejection episodes nor clinical manifestations of graft-versus-host disease...
  5. ncbi request reprint Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
    Laura J Johnston
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 11:47-55. 2005
    ..Given the significant toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be pursued in future cGVHD trials...
  6. pmc Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation
    Antonia M S Müller
    Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 107:14721-6. 2010
    ..These observations contradict the postulation that mature donor T cells provide important transient immunity and facilitate HSC engraftment...
  7. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
    ..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
  8. pmc The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
    Irving L Weissman
    Stanford Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA 94304 1334, USA
    Blood 112:3543-53. 2008
    ..Here we review the steps, from our viewpoint, that led to HSC isolation and its importance in self-nonself immune recognition...
  9. pmc Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma
    Sally Arai
    Department of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 16:1145-54. 2010
    ..This new transplant regimen for HL resulted in decreased BCNU toxicity with encouraging FFP and OS. A prospective, risk-modeled comparison of this new combination with other conditioning regimens is warranted...
  10. ncbi request reprint Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
    Susanne Auffermann-Gretzinger
    Division of Oncology and Bone Marrow Transplantation, Department of Medicine, The Blood Center, Stanford University Medical Center, CA 94305, USA
    Blood 99:1442-8. 2002
    ..This information has potential implications for manipulation of immune responses after allogeneic HCT...
  11. ncbi request reprint Approaches to transplantation tolerance in humans
    Samuel Strober
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5166, USA
    Transplantation 77:932-6. 2004
    ..Preclinical and clinical studies of the use of total lymphoid irradiation for the induction of chimeric and nonchimeric tolerance are summarized here...
  12. ncbi request reprint Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation
    Heather G Shilling
    Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 101:3730-40. 2003
    ..These results demonstrate that a majority of HLA-matched hematopoietic cell transplantations involve KIR mismatch and reveal differences in NK cell repertoire having potential impact for immune responsiveness and transplantation outcome...
  13. ncbi request reprint Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
    Christian Scheffold
    Department of Medicine, Division of Blood and Marrow Transplantation, University School of Medicine, Stanford, California 94305 5623, USA
    Biol Blood Marrow Transplant 11:1-12. 2005
    ..Furthermore, the chimerism data reinforce the importance of competition for HSC niches in conjunction with immune mechanisms in resistance to long-term HSC engraftment...
  14. pmc Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow
    Gabriel J Tsao
    Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California, USA
    Proc Natl Acad Sci U S A 106:3288-93. 2009
    ..We interpret these latter findings to show the importance of peripheral antigen presentation in the selection and maintenance of the T cell repertoire...
  15. ncbi request reprint Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation
    Caroline Arber
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, CA, USA
    Blood 102:421-8. 2003
    ..These data support the potential for composing grafts with committed progenitors to reduce susceptibility to viral infection following HCT...
  16. ncbi request reprint Protective conditioning for acute graft-versus-host disease
    Robert Lowsky
    Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1321-31. 2005
    ..Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans...
  17. ncbi request reprint Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants
    Georg F Beilhack
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA 94305 5623, USA
    Diabetes 54:1770-9. 2005
    ....
  18. ncbi request reprint Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation
    Maria T Millan
    Department of Surgery, Division of Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA
    Transplantation 73:1386-91. 2002
    ....
  19. ncbi request reprint CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Exp Hematol 33:279-85. 2005
    ..G-PBMC cell contents were analyzed for influence on outcomes...
  20. ncbi request reprint Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice
    Georg F Beilhack
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Diabetes 52:59-68. 2003
    ..These data demonstrate for the first time that purified HSC grafts block development of autoimmune diabetes and illuminate how HSC grafts alter thymic and peripheral T-cell responses against auto- and alloantigens...
  21. ncbi request reprint Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
    Steven M Horwitz
    Division of Oncology, Stanford University Medical Center, Ste 202, 1000 Welch Rd, Palo Alto, CA 94304, USA
    Blood 103:777-83. 2004
    ..Rituximab after HDT and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma...
  22. pmc Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation
    Alexander Filatenkov
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Immunol 183:7196-203. 2009
    ..In conclusion, these findings show that otherwise ineffective vaccination to solid nonhematologic tumors can be dramatically enhanced by HCT...
  23. pmc Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice
    Thai M Cao
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:11571-6. 2003
    ..Our results likely extend to all serologically MHC-matched mouse strains used in modern research and highlight the profound and variable influence that non-MHC genetic determinants can have in dictating outcome after HCT...
  24. ncbi request reprint Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98109 1024, USA
    J Clin Oncol 24:4150-7. 2006
    ..Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches...
  25. pmc Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 13:423-32. 2007
    ....
  26. ncbi request reprint Biology of hematopoietic stem cells and progenitors: implications for clinical application
    Motonari Kondo
    Department of Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Annu Rev Immunol 21:759-806. 2003
    ....
  27. ncbi request reprint Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
    Dietger Niederwieser
    Division of Hematology and Oncology, University of Leipzig, Germany
    Blood 101:1620-9. 2003
    ..HCT from HLA-matched or mismatched unrelated donors can be performed with a reduced intensity conditioning regimen in patients ineligible for conventional HCT...
  28. ncbi request reprint Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
    George E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Int J Hematol 76:184-9. 2002
    ..Related and unrelated nonmyeloablative HSCT is feasible and potentially curative in patients with advanced hematological malignancies who have no other treatment options...
  29. ncbi request reprint Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 129:381-91. 2005
    ..Patients with early-onset GVHD after non-myeloablative HCT from HLA-identical related donors might benefit from intensified primary immunosuppressive treatment...
  30. ncbi request reprint Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
    Ute Hegenbart
    University of Leipzig, Leipzig, Germany
    J Clin Oncol 24:444-53. 2006
    ....
  31. ncbi request reprint Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing
    Michael B Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 12:454-65. 2006
    ..Nonmyeloablative conditioning with postgrafting cyclosporine and MMF given 3 times daily allowed 95% durable engraftment of unrelated donor G-PBMC grafts...
  32. pmc Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning
    Frederic Baron
    University of Liege, Liege, Belgium
    Biol Blood Marrow Transplant 13:1041-8. 2007
    ..08 compared to the historical patients). We conclude that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning...
  33. ncbi request reprint HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
    Frederic Baron
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:272-9. 2005
    ..Further efforts are directed at reducing the risk of graft rejection by exclusive use of G-PBMC and increasing the degree of pretransplantation immunosuppression...

Research Grants18

  1. Barriers to Allogeneic Hematopoietic Stem Cell Engraftment
    JUDITH ANNE SHIZURU; Fiscal Year: 2010
    ..Based upon our understanding of the immune and non- immune barriers to engraftment we have a long-term goal of making allogeneic HCT safer and more effective for the treatment of malignant and non-malignant disease. ..
  2. Barriers to Allogeneic Hematopoietic Stem Cell Engraftment
    Judith Shizuru; Fiscal Year: 2009
    ..Based upon our understanding of the immune and non- immune barriers to engraftment we have a long-term goal of making allogeneic HCT safer and more effective for the treatment of malignant and non-malignant disease. ..
  3. Isolation and Transplantation of Candidate Alveolar Progenitor Cells
    Judith Shizuru; Fiscal Year: 2007
    ..abstract_text> ..
  4. Isolation and Characterization of Lung Alveolar Progenitors
    Judith Shizuru; Fiscal Year: 2007
    ..If successful the populations identified in these studies may be used as therapy for acute lung injury such as acute respiratory distress syndrome (ARDS), radiation pneumonitis, and chemotherapy induced lung injury. ..
  5. Barriers to Allogeneic Hematopoietic Stem Cell Engraftment
    Judith Shizuru; Fiscal Year: 2007
    ..Based upon our understanding of the immune and non- immune barriers to engraftment we have a long-term goal of making allogeneic HCT safer and more effective for the treatment of malignant and non-malignant disease. ..
  6. Diabetes Allele Transfer by Hematopoietic Cell Transpl.
    Judith Shizuru; Fiscal Year: 2006
    ..SCID mice or third party islets. We will further determine if insulin-producing cell clusters derived from embryonic stem cells can confer benefits similar to adult islets when transplanted in conjunction with hematopoietic cells. ..
  7. Hematopoietic cell Transplants for Autoimmune Diseases
    Judith Shizuru; Fiscal Year: 2005
    ..A further goal of this application is to understand the mechanism(s) by which the proposed autologous and allogeneic HCT regimens alter immune responses to autoantigens. ..
  8. Isolation and Transplantation of Candidate Alveolar Progenitor Cells
    JUDITH ANNE SHIZURU; Fiscal Year: 2010
    ..abstract_text> ..